6533b85ffe1ef96bd12c1e38

RESEARCH PRODUCT

PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease

Vincenzo Di MartinoRosaria Maria PipitoneRossella ZitoAntonio CraxìSalvatore PettaCalogero CammàFederica SpatolaGrazia PennisiStefania GrimaudoVito Di Marco

subject

Liver Cirrhosismedicine.medical_specialtyLiver fibrosisInflammationPolymorphism Single NucleotideGastroenterologyNon-alcoholic Fatty Liver DiseaseLiver stiffnessFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineHumansGenetic Predisposition to DiseaseIn patientHepatologybusiness.industryMetabolic riskGastroenterologyNASHMembrane ProteinsLipasemedicine.diseaseFibrosisLiverSteatosismedicine.symptombusiness

description

Liver fibrosis is the main predictor of events in patients with nonalcoholic fatty liver disease (NAFLD),1 and its evolution is characterized by a nonlinear trend2,3 mostly affected by metabolic risk factors, severity of liver inflammation and steatosis, and weight loss.3 The rs738409 C>G common variant in PNPLA3 gene has been associated with severity of fibrosis and risk of liver-related events in NAFLD.4,5 Noninvasive tests as Fibrosis-4 (FIB-4) and liver stiffness measurement (LSM) are useful to rule-out advanced fibrosis and they could be reliable to predict fibrosis progression.2,6 We aimed to evaluate in patients with NAFLD whether PNPLA3 rs738409 C>G variant impacts on fibrosis progression, noninvasively assessed by FIB-4 and LSM.

yearjournalcountryeditionlanguage
2020-08-29
10.1016/j.cgh.2020.09.009http://hdl.handle.net/10447/509970